InflaRx N.V. Common Stock
IFRXInflaRx N.V. is a biopharmaceutical company focused on developing and commercializing therapies that target inflammatory diseases. The company's pipeline mainly includes monoclonal antibodies designed to inhibit the complement system's role in inflammatory processes, aiming to treat conditions such as hidradenitis suppurativa and other severe inflammatory disorders. Headquartered in the Netherlands, InflaRx leverages its expertise in immunology to develop innovative treatments for unmet medical needs.
Company News
InflaRx N.V. (Nasdaq: IFRX) announced it received a notice from Nasdaq on March 11, 2026, indicating that its ordinary shares have closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until September 7, 2026, to regain compliance, with a potential additional 180-day grace period if it transfers to...
InflaRx announced that the Independent Data Monitoring Committee recommended stopping the Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. The company will focus on its oral inhibitor INF904 and consider cost-saving measures.
InflaRx N.V. announced the pricing of its public offering of 8,250,000 ordinary shares and 6,750,000 pre-funded warrants at $2.00 per share. The company intends to use the net proceeds to fund the clinical development of its pipeline candidates and for general corporate purposes.
InflaRx's anti-C5a antibody vilobelimab has received a positive opinion from the CHMP of the EMA for the treatment of SARS-CoV-2-induced ARDS. The positive opinion is based on the results of the PANAMO trial, which showed improved survival with vilobelimab treatment.
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for...
